A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers - Join Clinical Trial NCTNCT05544929
How to Join This Clinical Trial - NCTNCT05544929
Learn how to participate in this PHASE1 trial studying an investigational therapy for Carcinoma, Neoplasms, Melanoma, Carcinoma, Squamous Cell, Nasopharyngeal Carcinoma, Mesothelioma, Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Melanoma, Cutaneous Malignant, Anus Neoplasms, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms, Carcinoma, Ovarian Epithelial, Thymoma, Microsatellite Instability. This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Carcinoma, Neoplasms, Melanoma, Carcinoma, Squamous Cell, Nasopharyngeal Carcinoma, Mesothelioma, Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Melanoma, Cutaneous Malignant, Anus Neoplasms, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms, Carcinoma, Ovarian Epithelial, Thymoma, Microsatellite Instability. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Carcinoma, Neoplasms, Melanoma, Carcinoma, Squamous Cell, Nasopharyngeal Carcinoma, Mesothelioma, Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Melanoma, Cutaneous Malignant, Anus Neoplasms, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms, Carcinoma, Ovarian Epithelial, Thymoma, Microsatellite Instability
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE1 - Early safety study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT05544929 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 18 locations. Find a study site near you:
Clinical Research Site
Boston, Massachusetts 02114 - United States
Status: RECRUITING
Clinical Research Site
New York, New York 10015 - United States
Status: RECRUITING
Clinical Research Site
Pittsburgh, Pennsylvania 15232 - United States
Status: RECRUITING
Clinical Research Site
Nashville, Tennessee 37203 - United States
Status: RECRUITING
Clinical Research Site
Toronto, Ontario M5G 2M9 - Canada
Status: RECRUITING
Clinical Research Site
Guangzhou, Guangdong 510080 - China
Status: RECRUITING
Clinical Research Site
Beijing, 100036 - China
Status: RECRUITING
Clinical Research Site
Lyon, 69373 - France
Status: RECRUITING
Clinical Research Site
Dresden, 01307 - Germany
Status: RECRUITING
Clinical Research Site
Essen, 45147 - Germany
Status: RECRUITING
And 8 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE1 clinical trial for Carcinoma, Neoplasms, Melanoma, Carcinoma, Squamous Cell, Nasopharyngeal Carcinoma, Mesothelioma, Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Melanoma, Cutaneous Malignant, Anus Neoplasms, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms, Carcinoma, Ovarian Epithelial, Thymoma, Microsatellite Instability:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships